Altimmune, Inc. (ALT)
2.64
-0.03
(-1.12%)
USD |
NASDAQ |
Oct 07, 09:37
Altimmune Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | -105.2K% |
| September 30, 2025 | -380.3K% |
| June 30, 2025 | -442.9K% |
| March 31, 2025 | -391.5K% |
| December 31, 2024 | -463.6K% |
| September 30, 2024 | -456.9K% |
| June 30, 2024 | -492.8K% |
| March 31, 2024 | -487.9K% |
| December 31, 2023 | -85.52K% |
| September 30, 2023 | -5.71K% |
| June 30, 2023 | -267.7K% |
| March 31, 2023 | -95.59K% |
| December 31, 2022 | |
| September 30, 2022 | -1.18M% |
| June 30, 2022 | -251.3K% |
| March 31, 2022 | -60.72K% |
| December 31, 2021 | -728.8% |
| September 30, 2021 | -21.26K% |
| June 30, 2021 | -18.04K% |
| March 31, 2021 | -1.77K% |
| December 31, 2020 | -459.3% |
| September 30, 2020 | -604.8% |
| June 30, 2020 | -2.32K% |
| March 31, 2020 | -175.6% |
| December 31, 2019 | -711.5% |
| Date | Value |
|---|---|
| September 30, 2019 | -1.70K% |
| June 30, 2019 | -208.3% |
| March 31, 2019 | -70.96% |
| December 31, 2018 | -946.7% |
| September 30, 2018 | -89.25% |
| June 30, 2018 | -378.1% |
| March 31, 2018 | -117.9% |
| December 31, 2017 | -314.4% |
| September 30, 2017 | -651.3% |
| June 30, 2017 | -103.9% |
| March 31, 2017 | -1.53K% |
| December 31, 2016 | -282.4% |
| September 30, 2016 | -532.2% |
| June 30, 2016 | -228.4% |
| March 31, 2016 | -122.0% |
| December 31, 2015 | -97.78% |
| September 30, 2015 | -114.6% |
| June 30, 2015 | -203.6% |
| March 31, 2015 | 20.70% |
| December 31, 2014 | -144.0% |
| September 30, 2014 | -480.9% |
| June 30, 2014 | -12.00% |
| March 31, 2014 | -60.34% |
| December 31, 2013 | -121.1% |
| September 30, 2013 | -113.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Protalix Biotherapeutics, Inc. | 18.98% |
| Taysha Gene Therapies, Inc. | -- |
| Humacyte, Inc. | -9.06K% |
| Liquidia Corp. | 43.52% |
| Agenus, Inc. | -1.64% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -34.49% |
| Return on Assets | -29.57% |
| Return on Invested Capital | -31.22% |
| Return on Net Operating Assets | -5.10K% |